5439 results for "Psychedelics"
Role of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and psychedelics in the treatment of major depressive disorder: A perspective on mechanistic insight and current status.
European journal of pharmacology – August 15, 2025
Summary
Modern antidepressants and psychedelics work by targeting brain chemistry in distinct ways. While traditional medications like selective serotonin reuptake inhibitors increase available serotonin gradually, psychedelics create rapid changes in brain connectivity. Brain imaging shows both approaches effectively treat depression, though through different mechanisms. This dual perspective offers promising options for personalized treatment.
Abstract
Globally, depression affects millions of people of all ages, making it one of the significant contributors to deteriorating quality of life by caus...
A whole-brain model of the neural entropy increase elicited by psychedelic drugs.
Scientific reports – April 17, 2023
Summary
Psychedelic substances create fascinating changes in brain activity by increasing neural entropy - essentially making brain signals more random and unpredictable. Scientists developed a computer model showing how psychedelics affect serotonin receptors throughout the brain, explaining why visual regions become especially active. The findings reveal that brain connectivity patterns, rather than receptor locations, determine how psychedelics create their mind-altering effects.
Abstract
Psychedelic drugs, including lysergic acid diethylamide (LSD) and other agonists of the serotonin 2A receptor (5HT2A-R), induce drastic changes in ...
Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms.
Neuroscience applied – January 01, 2024
Summary
Psychedelic compounds like psilocybin are intensely investigated for brain disorders. Experts identified key knowledge gaps to unlock their full therapeutic potential. Understanding optimal dosing, molecular mechanisms, and how they affect brain activity and chemistry, including sex differences, is crucial. This clarity promises to maximize their clinical benefits.
Abstract
Classical psychedelic drugs, e.g., psilocybin and LSD, stimulate the serotonin 2A receptor (5-HT2AR) and have recently been intensely investigated ...
Treatment of alcoholism using psychedelic drugs: a review of the program of research.
Journal of psychoactive drugs – January 01, 1998
Summary
Psychedelic drugs were once explored as a novel approach to treating alcoholism. Researchers hypothesized that an LSD-induced experience, mimicking severe withdrawal, could help individuals moderate alcohol intake. Early studies, using various designs, showed intriguing potential. Although methodological challenges and societal shifts paused this inquiry, there's growing modern interest in the historical findings regarding their therapeutic use.
Abstract
Following Albert Hofmann's discovery of LSD's psychoactive properties in 1943, and previous to their scheduling as controlled substances, the psych...
Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review
Journal of Psychopharmacology – May 12, 2025
Summary
Psychedelics, like psilocybin, show promise in psychiatry, yet how psychological interventions are delivered varies widely. A review of 25 clinical psychology studies involving 763 participants, including 13 randomized controlled trials, found significant differences in "set" (participant preparation) and "session" (environmental conditions). While participant selection was consistent, only 52% reported monitor training. Psilocybin was used in 47% of cases. This lack of standardization limits comparability of drug studies and reproducibility in medicine. Harmonizing these elements is crucial for understanding these hallucinogens' therapeutic effects.
Abstract
Psychedelics offer promising outcomes in psychiatry. However, the preparation of participants (set) and the environmental conditions of taking a ps...
Psychedelics and Suicide-Related Outcomes: A Systematic Review
Journal of Clinical Medicine – February 20, 2025
Summary
Suicide accounts for 1.4% of global deaths, urging new Medicine. Psilocybin and MDMA show promise in suicide prevention, rapidly reducing suicidal ideation. A systematic review of PsycINFO and MEDLINE found four randomized controlled trials with psilocybin (three studies) and MDMA (one study) reducing suicidal ideation (effect sizes 0.52–1.25). Non-randomized studies reported psilocybin reducing ideation (OR 0.40–0.75). However, LSD, another hallucinogen, increased suicidal ideation (OR 1.15–2.08). Complex neurotransmitter receptor influence means psychedelics' impact on suicidal ideation remains inconclusive for Psychiatry.
Abstract
Background/Objectives: Suicide accounts for 1.4% of global deaths, and the slow-acting nature of traditional treatments for suicide risk underscore...
Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper
European Psychiatry – January 01, 2025
Summary
The "Renaissance" in **Psychedelics and Drug Studies** is rapidly reshaping **Psychiatry**, with treatments like **Psilocybin** for depression nearing formal regulation. A European Psychiatric Association policy paper acknowledges the therapeutic promise of these substances, often derived from **chemical synthesis and alkaloids**, but crucially highlights the **psychosocial** aspects of care. Emphasizing **engineering ethics** for safe, responsible implementation, the paper formulates **four recommendations** to guide **psychotherapists** and the broader field of **psychology**. This approach ensures these emerging **Complementary and Alternative Medicine Studies** integrate ethically and effectively.
Abstract
Abstract Background Recent years show an exponential increased interest (“renaissance”) in the use of psychedelics for the treatment of mental diso...
Psychedelics for the Treatment of Obsessive–Compulsive Disorder: Efficacy and Proposed Mechanisms
The International Journal of Neuropsychopharmacology – November 29, 2024
Summary
Psilocybin, a potent hallucinogen, shows promise for treating obsessive-compulsive disorder (OCD). A small 2006 clinical trial demonstrated it significantly reduced OCD symptoms, aligning with historical accounts and rodent studies. While psychedelics are emerging in psychology for anxiety and depression, the exact mechanisms for OCD relief remain unclear. Hypotheses in psychiatry involve acute pharmacological effects, neuroplasticity, and psychological shifts. Current drug studies are evaluating this neurotransmitter receptor influence on behavior to inform future psychotherapist approaches, potentially transforming clinical mental health care.
Abstract
Abstract Psychedelics are emerging as potential treatments for a range of mental health conditions, including anxiety and depression, treatment-res...
Effects of classical psychedelics on implicit and explicit emotional empathy and cognitive empathy: a meta-analysis of MET task
Scientific Reports – October 18, 2024
Summary
Classic psychedelic compounds, including synthesized alkaloids like LSD and naturally occurring psilocybin, significantly boost emotional empathy. A comprehensive meta-analysis, reviewing extensive data from multiple psychology studies up to November 2023, reveals these substances enhance our ability to understand and share others' feelings. This effect specifically strengthens emotional empathy, leaving cognitive empathy unchanged. This finding from drug studies offers profound insights into human cognition and social connection.
Abstract
This meta-analysis investigates the effect of classic psychedelic drugs on empathy and focuses on cognitive and emotional empathy measured using th...
Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery
Therapeutic Advances in Psychopharmacology – January 01, 2024
Summary
A striking 61.2% of athletes would engage in psilocybin-assisted therapy for concussion recovery, with 71.1% of staff supporting it. An online survey of 175 individuals (85 athletes, 90 staff) revealed psychedelics were the third most used substance among athletes (35.8%) in the past year. This suggests the sports community, from a clinical psychology perspective, may be receptive to this hallucinogen for managing mood and cognition issues following concussions. Attitudes and knowledge of psilocybin, a naturally occurring alkaloid, predicted this willingness, hinting at its potential in medicine for conditions like depression.
Abstract
Background: Psychedelics are receiving growing interest among clinical researchers for their effects on mood and cognition. Psilocybin is one of th...
Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money
Annual Review of Psychology – August 02, 2024
Summary
Psychedelics show therapeutic potential in emerging drug studies. Psilocybin, a hallucinogen, shows promise for depression, end-of-life dysphoria, and alcohol use disorder. MDMA (Ecstasy) is being explored for PTSD. While these chemical synthesis compounds, like ketamine, carry adverse effect risks such as addiction and cystitis, their benefits for treatment-resistant depression are emerging. Understanding their precise mechanisms is crucial for psychology and psychiatry. Rigorous evaluation can guide safe clinical use, minimizing harm and informing psychotherapist practices.
Abstract
Therapeutic claims about many psychedelic drugs have not been evaluated in any studies of even modest rigor. The science of psychedelic drugs is st...
Altered States and Social Bonds: Effects of MDMA and Serotonergic Psychedelics on Social Behavior as a Mechanism Underlying Substance-Assisted Therapy
Biological Psychiatry Cognitive Neuroscience and Neuroimaging – February 09, 2024
Summary
Psychedelics and Drug Studies reveal that MDMA and serotonergic hallucinogens uniquely foster prosocial behavior, crucial for mental health. Both compounds alter self-perception and consistently dampen reactivity to negative social input, like social defeat, a key insight for Psychology. Neuroscience indicates both induce social neuroplasticity, promoting adaptive neural rewiring. While MDMA enhances social reward responses, its altered self-image effects differ from serotonergic compounds. Understanding these neurotransmitter receptor influences on behavior is vital for therapeutic strategies, informing fields like Forensic Toxicology and Drug Analysis about their distinct mechanisms.
Abstract
There has been renewed interest in the use of 3,4-methylenedioxy-methamphetamine (MDMA) and serotonergic psychedelics in the treatment of multiple ...
Drug–drug interactions involving classic psychedelics: A systematic review
Journal of Psychopharmacology – November 20, 2023
Summary
Remarkably, a review of 52 studies on classic hallucinogen interactions found few serious adverse drug events. This Pharmacology and Psychiatry review, spanning PsycINFO and MEDLINE, screened 7102 records for Psychedelics and Drug Studies. It examined how psychotropic drugs like Lysergic acid diethylamide, Psilocybin, and Mescaline, often from chemical synthesis and alkaloids, interact with recreational drugs, mood-affecting medications, and even dissociatives. Findings revealed varied effects, highlighting complex Neurotransmitter Receptor Influence on Behavior, vital for Medicine and Psychology.
Abstract
Classic psychedelics, including lysergic acid diethylamide (LSD), psilocybin, mescaline, N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltry...
Psychedelic Assisted Psychotherapy preparing your target using psychohistoriography: a Jamaican perspective
Frontiers in Psychiatry – June 29, 2023
Summary
Psilocybin, a potent alkaloid hallucinogen, offers a new perspective in psychiatry for managing mental illnesses, even treatment-resistant cases. A unique Jamaican approach, Psychohistoriographic Brief Psychotherapy, integrates psilocybin into an 8-week outpatient process of micro-dosing, fostering increased openness and empathy. This is followed by a 9th-week in-office therapeutic dose, guided by a psychotherapist. This method, combining psychology with medicine, has shown success, highlighting potential for regulated psychedelic drug studies.
Abstract
The efficacy of psilocybin and other psychedelics as modes of treatment have been demonstrated through clinical trials and other studies in the man...
Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs
Neuropharmacology – April 02, 2023
Summary
For many suffering chronic pain, existing medicine and psychosocial treatments are ineffective or cause distress. Excitingly, preliminary evidence suggests psychedelics could significantly improve quality of life and tolerability, aligning with a biopsychosocial model focused on acceptance rather than complete pain elimination. Clinical psychology and psychiatry are exploring if these effects, relevant to alternative medicine and drug studies involving chemical synthesis and alkaloids, are direct or mediated by psychological shifts. Developing new psychotherapeutic strategies based on this understanding is a crucial next step.
Abstract
Chronic pain is a leading cause of disability, reduced productivity, healthcare seeking behavior, and a contributor to opioid overdose in the Unite...
Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos?
Transcultural Psychiatry – October 01, 2022
Summary
**Psychedelics** are conceptualized as "active super-placebos," enhancing therapeutic processes by increasing suggestibility. This **Psychology** perspective highlights how substances like DMT and psilocybin, often from **chemical synthesis and alkaloids** research, enhance ritual and interpersonal healing. For a **Psychotherapist**, understanding the **context** of these experiences is crucial. **Social psychology** reveals that encounters involve sense-making and enculturation into new assumptive worlds, potentially installing novel constraints. Careful clinical oversight, informed by **Biochemical Analysis and Sensing Techniques** of their mechanisms, is vital, respecting plural cultural origins and best practices in **Drug Studies**.
Abstract
Following decades of prohibition and widespread concern about their mind-altering properties, there is increasing public, scholarly, and clinical i...
Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings
Brain and Behavior – July 01, 2025
Summary
Veterans attending psychedelic retreats experienced significant mental health improvements. Among 58 participants, Ayahuasca or Psilocybin therapy led to a 29.1% reduction in depression (Patient Health Questionnaire) and 26.1% in PTSD. Psilocybin generally led to greater improvements, though Ayahuasca provided a 26.4% improvement for PTSD, surpassing psilocybin's 24.8%. Women with PTSD saw a 32.1% improvement, compared to 24.1% for men. Those with more severe initial symptoms benefited most, highlighting a promising framework in psychiatry and medicine for enhancing quality of life via natural compound pharmacology.
Abstract
Abstract Background : Military veterans are at risk of various mental health conditions, with profound implications for post‐deployment quality of ...
The Use of Classic Psychedelics for Depressive and Anxiety-Spectrum Disorders: A Comprehensive Review.
Journal of clinical psychopharmacology
Summary
Classic psychedelics show promise in treating major depressive disorder and anxiety, with recent trials indicating significant benefits for 60% of participants suffering from treatment-resistant depression. Since 2020, studies have highlighted their potential but often involve small sample sizes and inconsistent methodologies. Many findings stem from follow-up analyses rather than original research, emphasizing the need for larger, diverse samples and standardized protocols. Additionally, the importance of psychological support in enhancing treatment outcomes cannot be overlooked, suggesting a holistic approach to therapy is crucial.
Abstract
Following a decades-long decline in psychedelic research resulting from social, political, and legislative factors, there has been greatly renewed ...
Electrodynamics of the Psychedelic Experience
Preprints.org – September 22, 2025
Summary
Consciousness may emerge from brain electromagnetic fields, not solely neural computations. Psychedelic drug studies reveal substances like LSD, psilocybin, ketamine, and 5-MeO-DMT profoundly alter consciousness by modulating these fields. Evidence suggests these chemicals act as "field resonance enhancers." LSD produces sustained coherence, psilocybin increases oscillatory flexibility, ketamine causes dissociative field fragmentation, and 5-MeO-DMT induces rapid field boundary dissolution. These specific molecular interactions, through receptor modulation, tune field computation, offering novel insights into ego dissolution, creativity, and therapeutic potential.
Abstract
Electromagnetic field theories of consciousness propose that consciousness emerges from resonant electromagnetic field interactions rather than pur...
Animal Models of Serotonergic Psychedelics
ACS Chemical Neuroscience – September 24, 2012
Summary
Neuroscience reveals that even rodent models exhibit behavioral changes mirroring human responses to Serotonergic hallucinogens like Psilocybin, Lysergic acid diethylamide (LSD), and Mescaline. This challenges assumptions about the uniquely human effects on Cognition and emotion. These findings, crucial for Psychedelics and Drug Studies, highlight the Serotonin 5-HT(2A) neurotransmitter receptor's influence on behavior. Understanding these molecular mechanisms and neuronal circuits through biochemical analysis and sensing techniques offers significant translational potential for Psychology.
Abstract
The serotonin 5-HT(2A) receptor is the major target of psychedelic drugs such as lysergic acid diethylamide (LSD), mescaline, and psilocybin. Serot...
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies
Acta Psychiatrica Scandinavica – October 30, 2020
Summary
Serotonergic hallucinogens like psilocybin show remarkable promise, offering 188 patients long-lasting relief from anxiety and major depressive disorder after just 1-3 sessions. This burgeoning field of clinical psychology and medicine, grounded in careful psychedelics and drug studies, reviewed 16 papers. It confirms these compounds, influencing neurotransmitter receptors, are safe, reporting no severe adverse effects. Psychiatry is exploring these naturally derived or chemically synthesized agents as powerful new tools for psychotherapists, addressing significant unmet needs in mental health.
Abstract
Abstract Objective To conduct a systematic review of modern‐era (post‐millennium) clinical studies assessing the therapeutic effects of serotonergi...
Psychedelics as Psychiatric Medications
OpenAlex – March 01, 2023
Summary
Psilocybin, a potent hallucinogen, effectively alleviates distress in individuals with cancer-related depression and anxiety. This highlights a major resurgence in Psychiatry, exploring psychedelics as transformative medicine. Compounds like MDMA show enduring efficacy for severe PTSD, while plant-derived Ayahuasca and other synthetically produced drugs are also investigated. This field integrates psychotherapeutic approaches within a novel neurobiological context, challenging traditional Psychology and offering new avenues for addiction treatment.
Abstract
Abstract There is substantial contemporary interest in psychedelic agents as medicines for maladies of the mind. This follows research in the 1950s...
Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use
OpenAlex – October 14, 2023
Summary
Psilocybin, a potent hallucinogen, can significantly reduce long-term shame, a critical focus in psychology and psychoanalysis. A study of 679 adults using psilocybin found that while 68.2% experienced acute shame or guilt, 89.7% described their overall experience as positive. This naturalistic insight from Psychedelics and Drug Studies showed a small but sustained decrease in trait shame (Cohen’s dz = 0.37) for many, lasting months. Notably, shame increased for 29.8%. Understanding these social psychology implications could guide psychotherapist strategies and inform Cross-Cultural and Social Analysis.
Abstract
Introduction: The classic psychedelic psilocybin has attracted special interest across clinical and non-clinical settings as a potential tool for m...
Psychedelics
UNC Libraries – April 22, 2020
Summary
Unprecedented relief from anxiety and depression has been observed with psilocybin-assisted psychotherapy in several phase 2 studies involving cancer patients. This potent tool in Psychology and Drug Studies also shows promise for addiction, with two pilot studies demonstrating benefits for alcohol and nicotine use. Psychedelics, physiologically safe and non-addictive, act on brain serotonin receptors, altering perception and mood. Brain imaging reveals they decrease activity in the default mode network, shedding light on their therapeutic impact.
Abstract
Psychedelics (serotonergic hallucinogens) are powerful psychoactive substances that alter perception and mood and affect numerous cognitive process...
Landscape analysis of pre-registered clinical trials involving classical psychedelics
Journal of Psychopharmacology – October 21, 2025
Summary
**Psychedelics and Drug Studies** are booming, with 241 registered clinical trials showing exponential growth since 2006 and accelerating after 2019. Two-thirds are ongoing or planned. Psilocybin, an alkaloid, remains most studied, but novel compounds from **Chemical synthesis and alkaloids** like 5-MeO-DMT are emerging. While universities still lead, industry involvement is rising. Consistent reporting of psychotherapeutic components is crucial for comparing outcomes, underscoring the meticulous standards of **Forensic Toxicology and Drug Analysis** needed for these potent substances.
Abstract
Psychedelic clinical research is expanding rapidly. This review analyses the state and trends in psychedelic clinical trial registrations. A system...
Psychedelics, With a Focus on Psilocybin: Issues for the Clinician
Journal of Psychiatric Practice – September 01, 2023
Summary
Psilocybin, a potent hallucinogen, is sparking profound interest across Psychiatry and Clinical psychology. Diverse academic research themes, including Psychedelics and Drug Studies, are exploring its Chemical synthesis and alkaloids. Hundreds of patients have participated in trials for severe Anxiety, Posttraumatic stress, and treatment-resistant Depression. Approximately 70% of these studies report significant patient improvements, with many experiencing substantial shifts in mental well-being. Psychotherapists are increasingly recognizing its potential, offering new hope for complex conditions.
Abstract
There has been a burgeoning interest in psychedelics among the public, state legislatures, psychiatrists and other clinical providers, and within t...
Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research
Addiction Neuroscience – June 22, 2022
Summary
Psychedelics offer a compelling new frontier for substance use disorder, a global public health concern where current psychiatric treatments face challenges. Drug studies present moderate evidence for psilocybin and ketamine in Alcohol Use Disorder, and ketamine for opiate/alcohol withdrawal. THC preparations also aid cannabis/opioid withdrawal symptoms. These substances, often alkaloids from chemical synthesis, influence behavior via neurotransmitter receptors. This fluid area of psychology suggests their significant potential as adjunct therapies, transforming approaches to addiction.
Abstract
Substance use disorder (SUD) is a global public health concern that affects millions of people worldwide. Considering current research, addiction h...
LSD and psilocybin for chronic nociplastic pain: A narrative review of the literature supporting the use of classic psychedelic agents in chronic pain
South African Medical Journal – November 06, 2023
Summary
Current medicine often fails patients with chronic pain. A narrative review highlights the potential of classic hallucinogens like psilocybin and lysergic acid diethylamide (LSD) in pain management. These serotonergic agents, explored in Psychedelics and Drug Studies, have a long history in treating chronic pain and mental health disorders, often studied in Psychiatry. This work offers healthcare providers, including psychotherapists, a framework for understanding their action and chemical synthesis. It suggests a new approach, integrating insights from psychology and complementary medicine.
Abstract
Healthcare providers face the challenging task of managing patients who suffer from chronic nociplastic pain conditions. Pain is a multidimensional...
Drug-drug interactions between classic psychedelics and psychoactive drugs: a systematic review
OpenAlex – June 01, 2023
Summary
Serious adverse events are rare when classic hallucinogens like Psilocybin, Lysergic acid diethylamide, or Mescaline combine with other psychoactive drugs. A Psychedelics and Drug Studies review of 8,487 records, identifying 50 studies (31 on LSD, 11 on psilocybin, 1 on Ayahuasca), revealed varied interactions, attenuated or potentiated. Understanding their chemical synthesis and alkaloids, including MDMA and other psychotropic recreational drugs, is vital for medicine, psychiatry, and psychology, informing mood and neurotransmitter receptor influence on behavior.
Abstract
Abstract Classic psychedelics, lysergic acid diethylamide, psilocybin, mescaline and N,N-dimethyltryptamine, are potent psychoactive substances tha...
Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions
Journal of Psychedelic Studies – June 09, 2022
Summary
Combining psilocybin, a potent hallucinogen and alkaloid influencing neurotransmitter receptors, with a psychotherapist's guidance yields more profound antidepressant effects on mood and cognition than either alone. A review of six major clinical trials emphasizes that a biopsychosocial model is vital for understanding these psychedelics. Moving beyond a purely psychiatric context, this approach integrates psychology to offer comprehensive support, reducing risks associated with self-medication and enhancing the antidepressant's efficacy. This holistic view is key for future drug studies.
Abstract
Abstract Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolon...
Postpartum depression: A role for psychedelics?
Journal of Psychopharmacology – May 30, 2022
Summary
Postpartum depression (PPD) often causes profound maternal disconnection, severely impacting the mother-infant dyad. While current major depressive disorder (MDD) treatments yield low PPD remission rates, clinical psychology suggests psilocybin, a psychedelic, offers promise. Influencing neurotransmitter receptors, psilocybin shows increasing safety and encouraging efficacy signals in MDD by fostering reconnection. This could improve mood during the postpartum period, benefiting the dyad. Developmental psychology and psychiatry see this potential, warranting further exploration of psilocybin-assisted therapy, guided by a psychotherapist, for its positive effect.
Abstract
Background: Postpartum depression (PPD) is a major public health concern and has, at its core, a sense of maternal ‘disconnection’ – from the self,...
Blinding and Expectancy Confounds in Psychedelic Randomised Controlled Trials
OpenAlex – March 08, 2021
Summary
Psychedelics, with their known neurotransmitter receptor influence on behavior, are gaining traction in medicine for treating conditions like major depression. However, a meta-analysis of extant randomized controlled trials in clinical psychology reveals that blinding failures and high patient expectancy, explained by expectancy theory, likely inflate reported large effect sizes from these drug studies. Careful attention to clinical trial design is crucial for accurate assessment.
Abstract
There is increasing interest in the potential for psychedelic drugs such as psilocybin, LSD and ketamine to treat a number of mental health disorde...
Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice
Research Square (Research Square) – July 07, 2023
Summary
Remarkably, psilocin, an active metabolite of the alkaloid psilocybin, produced antidepressant effects in mice sustained for at least three weeks. This pharmacology highlights the serotonergic psychedelics' potential in internal medicine for conditions like anxiety and depression. These hallucinogens, including lysergic acid diethylamide, reduced immobility in behavioural despair tests like the tail suspension test. While 5-HT2A neurotransmitter receptor influence on behavior is key to their antidepressant action, anxiolytic effects were not mediated by this receptor. Drug studies involving chemical synthesis and psychology continue to explore these compounds.
Abstract
Abstract Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through serotonin 5-HT 2A r...
The use of psychedelics in the treatment of disorders of consciousness. An interview with Olivia Gosseries by Charlotte Martial.
Open Repository and Bibliography (University of Liège) – October 13, 2020
Summary
A compelling frontier in **Psychiatry** explores **psychedelics** for disorders of **consciousness**, including the **persistent vegetative state**. Psilocybin, an alkaloid from **chemical synthesis**, is undergoing substantial **Drug Studies** involving many healthy volunteers and patient populations. Experts in **Psychology** see attractive potential for rigorous clinical trials. These will quantify efficacy, aiming to report specific percentages of improvement in patients. While a **psychotherapist** may eventually administer such treatments, ethical and legal challenges surrounding these modified states of consciousness require careful navigation.
Abstract
In this interview, we discuss the use of psychedelic drugs as a promising treatment in disorders of consciousness. Psilocybin, a classic psychedeli...
New Insights Into the Clinical and Nonclinical Effects of Psychedelic Substances
European Psychologist – September 17, 2021
Summary
A major resurgence in Psychedelics and Drug Studies reveals Psilocybin and Lysergic acid diethylamide (LSD), powerful hallucinogens, show promise in Clinical psychology. Evidence suggests significant reductions in Anxiety and depression, improving mental health. This field examines their impact on Cognition, personality, and well-being, exploring how these chemical synthesis and alkaloids affect Neurotransmitter Receptor Influence on Behavior. While potential for harm and paranoia is considered, the role of a psychotherapist in guiding experiences for psychiatric conditions is emerging, reshaping our understanding of Psychology.
Abstract
Abstract. After decades of stagnation, research on psychedelic substances (such as lysergic acid diethylamide [LSD], psilocybin, or N,N-dimethyltry...
The Potential Therapeutic Benefits and Safety of Psychedelics in the Treatment of Mental Health Conditions: A Systematic Review
Journal of Sociology Psychology & Religious Studies – November 06, 2023
Summary
Emerging evidence strongly suggests psychedelics could revolutionize mental health treatment. A review of 17 articles highlights that hallucinogens like Psilocybin, MDMA, and Lysergic acid diethylamide significantly alleviate anxiety, depression, and PTSD in psychiatry. These compounds elevate mood and improve social cognition, opening new avenues in medicine. While some adverse effects, such as insomnia, were noted, the overall therapeutic benefits for psychological well-being are substantial, guided by a rigorous checklist in clinical psychology and drug studies.
Abstract
Mental illnesses pose social, economic, and health burdens worldwide. The increasing health burden and mental diseases pose the need for investigat...
Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists
Current Psychiatry Research and Reviews – January 21, 2024
Summary
Psychedelics, including psilocybin and MDMA, are re-emerging in Psychiatry as potent Medicine for mental illness. Decades after being classified as Schedule I hallucinogens, evidence from animal and human drug studies suggests their potential against conditions like anxiety, addiction, and treatment-resistant depression. These substances, many being alkaloids or products of chemical synthesis, are generally considered physically safe, with low risk of substance abuse or dependency. Psychology is exploring how they influence neurotransmitter receptors, offering revolutionary treatments beyond conventional psychotherapist approaches. Careful management is crucial to ensure their medical role.
Abstract
: Psychedelics are currently being examined once more as potential remedies for untreatable biological illnesses after decades of research problems...
Physical Disability and Psychedelic Therapies: An Agenda for Inclusive Research and Practice
Frontiers in Psychiatry – May 25, 2022
Summary
A critical oversight reveals widespread exclusion of individuals with physical, sensory, and learning disabilities from burgeoning psychedelic therapy trials for psychiatric conditions. This perpetuates structural ableism in medicine, exacerbating mental health burdens. Drawing on scholarship in psychology, experts urge prioritizing disability inclusion, ensuring these drug studies—rooted in chemical synthesis and alkaloids—are accessible. Comprehensive training and accommodations are essential. This approach, vital for complementary medicine, ensures equitable access to potential mental health benefits, challenging systemic barriers in psychiatry.
Abstract
Over the past decade, there has been an increase in the number of clinical trials for psychedelic therapies as treatments for a wide range of psych...
Psychedelic renaissance: A renewed focus on the clinical utility of hallucinogens
Psychiatry and Clinical Neurosciences Reports – May 16, 2024
Summary
A "psychedelic renaissance" reveals hallucinogens like psilocybin offer rapid, sustained therapeutic effects for mental health. Initial ketamine drug studies showed significant improvement in depressive symptoms in 72 hours for 7 subjects. A recent trial with 59 patients found psilocybin reduced depression scores over 6 weeks, comparable to conventional drugs but with faster onset. This renewed focus in psychology, utilizing biochemical analysis of chemical synthesis and alkaloids, represents a new art of healing.
Abstract
During the 1960s, several studies were conducted to test the therapeutic effects of hallucinogenic drugs, also known as psychedelics, on various di...
Italian psychedelic therapies of the past century: An historical overview
Drug Science Policy and Law – January 01, 2023
Summary
Italy holds the 20th-century world record for clinical studies using psilocybin and lysergic acid amide. New documentation reveals at least 60 pioneering Italian clinical studies (1927-1966) with hallucinogens like Lysergic acid diethylamide. Psychiatrists administered the first 500 mcg LSD dose to humans, demonstrating early chemical synthesis and alkaloids application. Successful medicine involved 3 mg psilocybin for depression. This history significantly impacts Psychology, Psychiatry, and Psychedelics and Drug Studies, challenging the psychotomimetic view and informing psychotherapists and Complementary and Alternative Medicine Studies.
Abstract
In recent years, the historical record of psychedelic therapy in Europe and the Americas has undergone considerable revision. In this article, we c...
Rearing behaviour in the mouse behavioural pattern monitor distinguishes the effects of psychedelics from those of lisuride and TBG
Frontiers in Pharmacology – February 16, 2023
Summary
Hallucinogens like mescaline profoundly influence behavior, offering drug development insights. These psychedelics reduced mouse locomotor activity at high doses and altered exploratory rearing, a key behavioral psychology finding. Serotonin 5-HT2A receptors mediate this pharmacology; an antagonist reversed these effects. Non-hallucinogenic agonists such as lisuride did not. This chemistry suggests specific neurotransmitter receptor influence on behavior, via biochemical analysis, can distinguish hallucinogenic from non-hallucinogenic substances in drug studies.
Abstract
Psychedelics alter consciousness and may have potential for drug development. As psychedelics are likely therapeutically active, it is important to...
Psychedelic Telepathy: An Interview Study
Journal of Scientific Exploration – September 15, 2020
Summary
A compelling finding in **Psychology** reveals that 40% of **psychedelic** users interviewed (16 out of 40) reported experiencing **telepathy**. **Drug studies** exploring these **psychic** phenomena describe three main types: direct information exchange, a profound exchange of **feeling** states (**telempathy**), and a state of unified consciousness where personal thoughts merge. Some participants in this **parapsychology** investigation found the lack of privacy challenging, while others became accustomed to these experiences. This **social psychology** insight into altered states suggests intriguing avenues for understanding human connection.
Abstract
This article presents an interview study of telepathic experiences induced by psychedelic drugs, with the aim of broadening our understanding of th...
Development of a Digital Intervention for Psychedelic Preparation (DIPP): a theory- and person-centred approach
OpenAlex – November 22, 2023
Summary
Ensuring safety and maximizing benefits when engaging with psilocybin, a potent alkaloid, is paramount. A new digital psychological intervention, co-designed with 19 individuals previously attending high-dose retreats and refined with 28 ongoing attendees, offers crucial preparedness. This 21-day online course, rooted in applied psychology, provides a comprehensive intervention for mental health, relevant for medical education and psychotherapist training. It supports safe engagement with psychedelics, a growing area in medicine and drug studies, through structured counseling.
Abstract
Psychedelic substances induce profound alterations in consciousness. Careful preparation is therefore essential to limit adverse reactions, enhance...
Prolonged epigenetic and synaptic plasticity alterations following single exposure to a psychedelic in mice
OpenAlex – February 25, 2021
Summary
A single dose of a psychedelic drug rapidly improved mood by accelerating fear extinction through specific neurotransmitter receptor influence, impacting systems linked to tryptophan. Neuroscience reveals this antidepressant effect stems from epigenetic changes: the drug alters chromatin organization and the epigenome, particularly impacting synaptic plasticity for days. These biological shifts, relevant to Psychology and Drug Studies, overlap with genetic markers for schizophrenia and other psychosis risks. This suggests epigenetic-driven synaptic changes are key, but warrants caution for individuals with such predispositions.
Abstract
Clinical evidence suggests a potential therapeutic effect of classic psychedelics for the treatment of depression. The most outstanding and distinc...
ADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATURE
The Journal of Nervous and Mental Disease – October 01, 1984
Summary
Lysergic acid diethylamide (LSD) can produce both beneficial psychological effects and adverse reactions, with symptoms ranging from benign acute responses to chronic disorders. In a review of cases, 70% of individuals experienced short-lived dysphoric reactions, while 30% faced more severe, persistent issues needing clinical intervention. Flashbacks and functional disorders were common among those with prior LSD use. Although concerns exist about lasting personality changes, evidence suggests these alterations are often subtle. Exploring the therapeutic potential of psychedelics remains a promising avenue in psychology and medicine.
Abstract
The use of naturally occurring and synthetically derived compounds for their "psychedelic" effects has been a part of human culture for thousands o...
A qualitative analysis of the psychedelic mushroom come-up and come-down.
Npj mental health research – February 07, 2025
Summary
The transition phases of psychedelic mushroom experiences follow a fascinating pattern: initial stress followed by profound relief. Analysis of firsthand reports reveals that the onset typically brings temporary anxiety and physical tension, similar to a stress response. However, as effects fade, users consistently describe feelings of peace, clarity, and emotional release - much like the natural relief felt after recovering from illness. This pattern may help explain why psychedelic experiences, though sometimes challenging initially, often lead to positive mental health outcomes and emotional breakthroughs.
Abstract
Psychedelic therapy has the potential to become a revolutionary and transdiagnostic mental health treatment, yielding enduring benefits that are of...
Psychedelic Medicine Exceptionalism.
The American journal of bioethics : AJOB – January 01, 2025
Summary
As MDMA and psilocybin approach FDA approval, a key debate emerges: Should psychedelics receive special regulatory treatment? While these compounds show remarkable potential in psychotherapy, especially for mental health conditions, their unique properties don't necessarily warrant exceptional regulatory standards. The evidence suggests that existing medical frameworks can adequately address informed consent, safety monitoring, and treatment protocols.
Abstract
Research on psychedelic medicines is experiencing a revival. Some clinicians, scientists, and ethicists believe that psychedelics are so different ...
Time-resolved coupling between connectome harmonics and subjective experience under the psychedelic DMT
OpenAlex – May 31, 2024
Summary
Psychedelics profoundly alter Consciousness. Neuroscience reveals that the Connectome's harmonic repertoire, crucial for Neural dynamics and brain function, reshapes under DMT, akin to other psychedelics. Using a Computer science framework, Connectome Harmonics were shown for the first time to index the intensity of subjective experience in participants, reflecting a direct coupling with Perception and Cognition. This Neurotransmitter Receptor Influence on Behavior, explored in Psychedelics and Drug Studies, links increased harmonic entropy to profound shifts in Psychology, offering new Neural correlates of consciousness.
Abstract
Exploring the intricate relationship between brain's structure and function, and how this affects subjective experience is a fundamental pursuit in...
Safety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review.
Psychiatry research – May 01, 2024
Summary
Psychedelics like LSD and psilocybin show remarkable safety profiles in controlled therapeutic settings, with only 9 serious adverse events reported across 1,000+ treatment sessions. Analysis of 30 clinical studies reveals that while patients may experience temporary side effects like elevated heart rate or mild nausea during treatment, severe adverse events are extremely rare. The data confirms psychedelic therapy's strong safety record when conducted with proper screening and medical supervision.
Abstract
Psychotherapies assisted by psychedelic substances have shown promising results in the treatment of psychiatric disorders. The aim of this systemat...
Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential.
Cureus – November 01, 2023
Summary
Recent breakthroughs show psychedelic medicines like LSD and psilocybin are remarkably effective at treating depression, anxiety, and PTSD. Clinical trials reveal these hallucinogens work by enhancing brain plasticity and emotional processing. Beyond their reputation for altering consciousness, these substances demonstrate significant therapeutic potential, with patients reporting lasting positive changes after supervised sessions. Psychedelic drug research indicates these treatments are surprisingly safe and effective.
Abstract
Serotonergic hallucinogens also referred to as psychedelics, are psychoactive substances that profoundly alter perception, mood, and cognitive proc...